CTRI/2020/05/025332招募中2 期
Ashwagandha for the Prophylaxis against SARS-CoV-2 Infection: A Randomized Hydroxychloroquine Controlled Clinical Trial in Health Care Providers
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Participants of either sex, 20 to 69 years of age
- •2.Participants tested negative for COVID-19 by nose and throat swab using RT PCR technique
- •3.HCQ naïve participants
- •4.Willing to come for regular follow â?? up visits
- •5.Written Informed Consent
排除标准
- •1.Participants with hypersensitivity or Intolerance and contraindications (psoriasis, porphyria and Glucose-6-Phosphate Dehydrogenase deficiency)
- •2.Pregnant women, lactating women and women of child bearing potential not willing to follow adequate contraception
- •3.Participants with known allergy or contraindication to Ashwagandha
- •4Have any Chronic,Severe,Unstable,Uncontrolled medical disease such as Diabetes Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the participant at increased risk during the study
- •5.History of having received any investigational drug in the preceding one month.
- •6.Prolonged concurrent intake of any drug that is known to prolong QT interval on the ECG as per physician discretion and these drugs include anti-arrhythmic drugs, quinidine, chlorpromazine, haloperidol, olanzapine, thioridazine, fluoxetine, antibiotics belonging to quinolone and macrolide family, antibiotics, fenfluramine and other appetite suppressants, Beta-2 agonists, terfenadine and other anti- histaminic drugs, liquorice and potassium loweringdrugs
- •7.History of taking any kind of Ayurvedic formulation or any other form of CAM (Complementary Alternative Medicine) therapy in the preceding 2 months
- •8.Unwilling to come for regular follow-up for the entire duration of the study.
- •9.Non â?? co-operative attitude of the participant
- •10.Any condition that, in the opinion of the investigator, does not justify the participantâ??s inclusion in the study.
- •Liver enzymes > 1.5 times of upper normal limits, Serum creatinine > 2 mg/dL, Blood urea > 70 mg/dL
研究者
相似试验
尚未招募
2 期
Prophylactic study of Ashwagandha and HCQ in health care providersCTRI/2020/09/028007CSIR Ministry of Ayush
尚未招募
不适用
Will colchicine be useful as an agent to prevent SARS-CoV-2 infection in kidney failure patients who are on maintenance hemodialysis?CTRI/2021/05/033605CMC Fluid research Funding
进行中（未招募）
2 期
Ashwagandha in the prevention of COVID-19 in Health Care workersCTRI/2020/08/027163Ministry Of AYUSH CCRAS
已完成
3 期
Clinical study to evaluate the effect of Ayurveda intervention as a prophylaxis for COVID-19 in Healthcare workersCTRI/2020/10/028424Ministry Of AYUSH Government of India
进行中（未招募）
1 期
EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalSCOVID-19MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001385-11-ESPlan Nacional Sobre SIDA4,000